Clinical Trials
46 trialsRICE
University of Cologne
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
DEDALUS
Fondazione IRCCS Policlinico San Matteo di Pavia
WIRE
Cambridge University Hospitals NHS Foundation Trust
PANDORA
AUSL Romagna Rimini
VIVA
Ospedale Policlinico San Martino
ESPADURVA
University Hospital, Essen
ILLUMINATE
University of Sydney
MILES-5
National Cancer Institute, Naples
RADIANT
Ottawa Hospital Research Institute
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Yonsei University
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
BOLD
ARCAGY/ GINECO GROUP
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
Beijing Haidian Hospital
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Samsung Medical Center
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
DUREC
Grupo Espanol Multidisciplinario del Cancer Digestivo
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The University of Hong Kong
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
DOMEC
Leiden University Medical Center
ARCADIA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
PRIME-RT
Cancer Research UK, Glasgow
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The University of Hong Kong
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Zhejiang Cancer Hospital
Adjuvant Durvalumab for Esophageal Cancer
Samsung Medical Center
DESC
Instituto do Cancer do Estado de São Paulo
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Singapore General Hospital
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Italian Network for Tumor Biotherapy Foundation